Primary Versus Secondary Metal Stent Implantation in PTBD
Launched by THERESIENKRANKENHAUS UND ST. HEDWIG-KLINIK GMBH · Aug 1, 2021
Trial Information
Current as of July 01, 2025
Completed
Keywords
ClinConnect Summary
Percutaneous transhepatic biliary interventions (PBI) are used in biliary tract diseases when endoscopic access was not successful or not possible due to anatomical changes after abdominal surgery. Self-expandible metal stents (SEMS) can be applied percutaneously in patients with malignant extrahepatic bile duct obstruction. In this setting, PTBD is usually performed as a two step-procedure with primary drainage of the accumulated bile fluid by an external or an external/internal plastic stent and a secondary metal stent implantation at an interval of a few days. PTBD with primary metal ste...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • PTBD with metal stent implantation into the extrahepatic bile duct
- • malignant and non-resectable extrahepatic bile duct obstruction
- Exclusion Criteria:
- • benign extrahepatic bile duct obstruction
About Theresienkrankenhaus Und St. Hedwig Klinik Gmbh
Theresienkrankenhaus und St. Hedwig-Klinik GmbH is a leading healthcare institution based in Germany, renowned for its commitment to providing high-quality medical care and advancing clinical research. With a rich history of excellence in patient treatment and innovative medical practices, the organization conducts a range of clinical trials aimed at enhancing therapeutic options and improving health outcomes. Their multidisciplinary team of healthcare professionals collaborates closely with researchers to ensure rigorous adherence to ethical standards and regulatory compliance, fostering an environment that prioritizes patient safety and scientific integrity. Through its clinical trial initiatives, Theresienkrankenhaus und St. Hedwig-Klinik GmbH strives to contribute to the advancement of medical knowledge and the development of effective treatment modalities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mannheim, , Germany
Patients applied
Trial Officials
Daniel Schmitz, MD
Principal Investigator
Theresienkrankenhaus Mannheim, University of Heidelberg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials